Vanguard Group Inc Esperion Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.97 Trillion
- Q2 2025
A detailed history of Vanguard Group Inc transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 11,716,829 shares of ESPR stock, worth $31.6 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,716,829
Previous 11,487,729
1.99%
Holding current value
$31.6 Million
Previous $16.5 Million
30.59%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding ESPR
# of Institutions
181Shares Held
106MCall Options Held
139KPut Options Held
604K-
Black Rock Inc. New York, NY14MShares$37.8 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT10.3MShares$27.9 Million0.05% of portfolio
-
Two Seas Capital LP Rye, NY9.95MShares$26.9 Million0.18% of portfolio
-
Pender Fund Capital Management Ltd. Vancouver, A16.68MShares$18 Million4.26% of portfolio
-
Marshall Wace, LLP London, X05.31MShares$14.3 Million0.01% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $180M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...